This website is intended for healthcare professionals only.

Hospital Pharmacy Europe     Newsletter          

Oncology

Rucaparib offers survival advantage over usual care in metastatic prostate cancer
Rucaparib offers survival advantage over usual care in metastatic prostate cancer
Read more
Poor cardiovascular risk control identified in half of men with prostate cancer
Poor cardiovascular risk control identified in half of men with prostate cancer
Read more
Pembrolizumab shows benefit in high-risk BCG non-responsive bladder cancer
Pembrolizumab shows benefit in high-risk BCG non-responsive bladder cancer
Read more
Darolutamide improves overall survival in metastatic hormone sensitive prostate cancer
Darolutamide improves overall survival in metastatic hormone sensitive prostate cancer
Read more
Neoadjuvant nivolumab provides significant 5-year overall survival in lung cancer
Neoadjuvant nivolumab provides significant 5-year overall survival in lung cancer
Read more
RCT shows Ide-cel effective in refractory or relapsed multiple myeloma
RCT shows Ide-cel effective in refractory or relapsed multiple myeloma
Read more
Novel prostate cancer screening test highly accurate
Novel prostate cancer screening test highly accurate
Read more
Single low-dose CT scan helps predict future lung cancer risk
Single low-dose CT scan helps predict future lung cancer risk
Read more
Yescarta approved by NICE for relapsed/remitted lymphomas
Yescarta approved by NICE for relapsed/remitted lymphomas
Read more
T cell biomarker predicts CAR T cell therapy response in relapsed lymphoma
T cell biomarker predicts CAR T cell therapy response in relapsed lymphoma
Read more
CTX-009 shows promise in biliary tract cancer
CTX-009 shows promise in biliary tract cancer
Read more
Glyphosate use associated with elevated biomarkers of oxidative DNA damage
Glyphosate use associated with elevated biomarkers of oxidative DNA damage
Read more
Infusion of novel agent reduces oral mucositis following chemoradiotherapy
Infusion of novel agent reduces oral mucositis following chemoradiotherapy
Read more
Contrast-enhanced CT enables prediction of treatment response in liver cancer
Contrast-enhanced CT enables prediction of treatment response in liver cancer
Read more
MRI guided stereotactic radiotherapy superior to CT in prostate cancer
MRI guided stereotactic radiotherapy superior to CT in prostate cancer
Read more

Popular articles

Government commits to easing pressure on NHS through commercial clinical trial investment
Biobank pilot to be launched by MHRA to better understand genetics and medicines safety
Understanding the intricacies of tube feeding with Stephen Taylor





 

Download Hospital Healthcare Europe free app

Download our app from the Apple App Store Download our app from Google Play

In official association with

HOPE Logo Footer

© Cogora 2023
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora